COMMUNIQUÉS West-GlobeNewswire

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Decembre 2023
17/01/2024
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]
NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
17/01/2024
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today [...]
Apollomics to Participate in a Fireside Chat at the B. Riley Securities’ 2024 Virtual Oncology Conference
17/01/2024
FOSTER CITY, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat cancers, today [...]
Aravive, Inc. to Delist from The Nasdaq Stock Market
17/01/2024
HOUSTON, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), announced today that the Company intends to voluntarily terminate the listing of its common stock on the Nasdaq Global Select [...]
Nyxoah Announces 2024 Strategic Priorities
17/01/2024
Nyxoah Announces 2024 Strategic Priorities Mont-Saint-Guibert, Belgium – January 17, 2024, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company [...]
Nyxoah Annonce ses Priorités Stratégiques pour 2024
17/01/2024
Nyxoah Annonce ses Priorités Stratégiques pour 2024 Mont-Saint-Guibert, Belgique – 17 janvier 2024, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») opère dans le [...]
R1 RCM Completes Acquisition of Acclara, Providence’s Modular Services Business
17/01/2024
Company Enters 10-Year Agreement to Provide Comprehensive Revenue Cycle Management Services to Providence Company to Release Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Outlook on February 27 [...]
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
17/01/2024
First patient dosed in company’s second clinical program with initial data expected in second half of 2024 Cash runway extended into second half of 2025 with clinical trials on track CAMBRIDGE, Mass., Jan. 17, 2024 ( [...]
Immatics Announces Proposed Public Offering
17/01/2024
Houston, Texas and Tuebingen, Germany, January 17, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer [...]
Nextech Med Spa Software Launches Industry's Most Sophisticated Client Photo Functionalities
17/01/2024
TAMPA, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Nextech today announced its med spa software now offers industry-leading photo management functionality for med spas that are ready to start the new year with new ways to [...]
Starton Therapeutics Announces STARTICLES Filing
17/01/2024
STARTICLES, referring to proprietary and novel solid-state particulates suspended within a drug-in-adhesive patch for delivery of active pharmaceutical ingredients (API) developed by Starton Therapeutics. STARTICLES is [...]
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
17/01/2024
Regulated Information Leuven, BELGIUM – January 17, 2024 – 7:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency [...]
EUROBIO SCIENTIFIC CONFIRME SON ELIGIBILITE AU DISPOSITIF PEA-PME
17/01/2024
EUROBIO SCIENTIFIC CONFIRME SON ELIGIBILITE AU DISPOSITIF PEA-PME Paris, le 17 janvier 2024 – 17h45 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro [...]
Eurobio Scientific : BILAN SEMESTRIEL S2 DU CONTRAT DE LIQUIDITE
17/01/2024
BILAN SEMESTRIEL S2 DU CONTRAT DE LIQUIDITE Paris, le 17 janvier 2024 – 17h45 Au titre du contrat de liquidité portant sur les actions de la société EUROBIO SCIENTIFIC (FR0013240934 – ALERS FP) confié à TP ICAP (Europe [...]
VIRBAC: Annual revenue growth of +4.9% thanks to record fourth-quarter activity at +11.5%
17/01/2024
KEY FIGURES Annual Revenue 2023 €1,246.9 million Growth at constant exchange rates and scope 1 +4.9% of which companion animals +3.5% farm animals +6.7% Growth at constant exchange rates +4.9% Overall change +2.5% 1 [...]
VIRBAC: Croissance du chiffre d’affaires annuel à +4,9% grâce à un niveau record d’activité au quatrième trimestre à +11,5%
17/01/2024
CHIFFRES CLÉS Chiffre d’affaires annuel 2023 1 246,9 M€ Croissance à taux de change et périmètre constants 1 +4,9% dont animaux de compagnie +3,5% animaux d’élevage +6,7% Croissance à taux de change constants +4,9% [...]
Postponement of the decision on the adoption of a sale plan (plan de cession) and the opening of judicial liquidation proceedings to January 31, 2024
17/01/2024
Postponement of the decision on the adoption of a sale plan ( plan de cession ) and the opening of judicial liquidation proceedings to January 31, 2024 Paris, France, January 17, 202 4 – 5:00 pm (CET) – Pixium Vision SA [...]
Report de la décision concernant l’arrêté d’un plan de cession et l’ouverture d’une procédure de liquidation judiciaire au 31 janvier 2024
17/01/2024
Report de la décision concernant l’arrêté d’un plan de cession et l’ouverture d’une procédure de liquidation judiciaire au 31 janvier 2024 Paris, France, 17 janvier 2024 – 17h00 CET – Pixium Vision SA (Euronext Growth [...]
Zealand Pharma major shareholder announcement: J O Hambro Capital Management
17/01/2024
Company announcement – No. 4 / 2024 Zealand Pharma major shareholder announcement: J O Hambro Capital Management Copenhagen, Denmark, 17 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78 [...]

Pages